A phase I multicenter single-arm trial has just opened enrollment for adult AML patients with TP53 mutation, evaluating safety and efficacy of DEC plus VEN, followed by DEC maintenance at dose of 5mg/m2 for 5 consecutive days every 6-8 weeks, for a total of 4 or 6 courses and DLI in case of MRD positivity. This evidence concerns the gene TP53 and acute myeloid leukemia.